Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2007

Organon Extends Research Interest in China

  • Huya Bioscience will support Organon in the sourcing and development Chinese pharmaceutical or biopharmaceutical compounds in three specific therapeutic areas. As part of this collaboration, Organon has acquired an equity interest in Huya.

    David Nicholson, executive vp R&D at Organon points out that this collaboration agreement “is consistent with our research strategy to forge closer links with China's highly skilled and motivated scientists and significantly expands our own ongoing biotech research programs and capabilities.”

    This transaction follows other research collaborations that Organon has signed with Chinese biotech companies, such as Shanghai Genomics and HD Biosciences.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »